McKesson Corporation vs NetFlix Inc — how do they compare? McKesson Corporation trades at $938.84 (market cap $108.46B), while NetFlix Inc trades at $70.3 (market cap $298.01B). The key difference: NetFlix Inc is far larger — about 2.7× McKesson Corporation's market cap, and McKesson Corporation pays a 0.4% dividend while NetFlix Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold McKesson Corporation for 74 Days and NetFlix Inc for 125 Days on average.
| MCK | NFLX | |
|---|---|---|
Market Cap | $108.46B | $298.01B |
Volume | 712,607 | 45,805,108 |
Sector | Health | Media |
52-Week High | $995.69 | $124.13 |
52-Week Low | $725.17 | $67.06 |
Typical Hold Time | 74 Days | 125 Days |
Enterprise Value | $115.00B | $303.19B |
Dividend Yield | 0.4% | — |
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $938.84, up 3.13% with strong technical momentum and bullish analyst sentiment. The stock shows consistent earnings beats with Q2 2026 EPS of $9.93 exceeding expectations of $9.56. Recent news highlights the extension of McKesson's pharmaceutical distribution agreement with CVS Health through 2032, reinforcing long-term revenue visibility. Revenue growth remains robust, climbing from $264.0B in 2022 to $359.1B in 2025, though net margins are thin at 1.12%.
The outlook is positive with 81% analyst buy ratings and a $956.43 consensus price target. Key risks include margin pressure from drug pricing policies and high current liabilities of $61.60B. The stock's valuation at 24.95x P/E appears reasonable given earnings growth projections, but investors should monitor debt levels and regulatory developments in healthcare distribution.
Netflix (NFLX) trades at $71.58, up 2.7% with strong fundamentals including 49.5% ROE and consistent earnings beats. The stock faces technical headwinds with bearish moving averages despite positive sentiment from institutional buying. Recent news highlights Netflix's live sports strategy and content investments, while analyst consensus remains bullish with a $89.78 price target representing 25% upside potential from current levels.
Netflix presents a compelling growth story with expanding profit margins and robust cash flow generation. Key risks include intensifying streaming competition and content cost pressures. The company's scale advantages and pricing power support premium valuation, though technical indicators suggest near-term consolidation may precede further upside.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →Netflix Inc. is an Internet subscription service for watching television shows and movies. Subscribers can instantly watch unlimited television shows and movies streamed over the Internet to their televisions, computers, and mobile devices and in the United States, subscribers can receive standard definition DVDs and Blu-ray Discs delivered to their homes.
Read more on NFLX →